Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care is organized by i3 Health.
Dates Available:
August 19, 2025 - August 18, 2026
Statement of Need:
Neuroendocrine tumors (NETs) are a heterogeneous group of rare tumors that originate from epithelial or nervous cells in the neuroendocrine system. They can arise from any organ, most commonly the gastrointestinal tract and lungs. Clinical presentation of NETs is highly variable, and patients can experience a broad spectrum of symptoms that significantly impact well-being and make diagnosis challenging. The last decade has seen progress in therapy for NETs based on improved pathological categorization and molecular understanding, resulting in increasing therapeutic choices. Therefore, it is crucial for clinicians to remain up to date on emerging diagnostic techniques and therapies to improve outcomes for their patients with NETs (Sultana et al, 2023). This actlvity, presented by Aman Chauhan, MD, Associate Professor of Medical Oncology, Leader of the Neuroendocrine Tumor Program, and Co-Director of the Theranostics Program at the University of Miami, Sylvester Comprehensive Cancer Center, will explore strategies for optimizing NET outcomes by closing the gaps in diagnosis and care.
Learning Objectives:
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
Aman Chauhan, MD, discloses that he has served on an advisory board or panel for Boehringer Ingelheim, Curium, Exelixis, Novartis, Sanofi, and Seneca Therapeutics.
The i3 Health planners, reviewers, and managers have nothing to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
UNAPPROVED USE DISCLOSURE
i3 Health requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT
This educational activity is supported by a medical education grant from Exelixis, Inc.
Aggregate participant data will be shared with commercial supporters of this activity.
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.